Zydus Cadila receives USFDA nod for Emtricitabine & Tenofovir Disoproxil Fumarate tablets

Zydus Cadila, a global pharmaceutical company, announced today that it has received USFDA approval to market Emtricitabine & Tenofovir Disoproxil Fumarate tablets.

Emtricitabine tablets would be available in three strengths of 100 mg, 133 mg & 167 mg. On the other hand, Tenofovir Disoproxil Fumarate tablets would be available in the strengths of 150 mg, 200 mg, and 250 mg.   

These tablets are used with other HIV medications to keep HIV infection in control. They help to reduce the amount of HIV in the patient’s body so that his immune system can function better.   

The tablets will be manufactured at the company’s formulation manufacturing facility located at SEZ, Ahmedabad. With this development, the company’s approvals now stand at 319. Along with this, the company has filed over 400 abbreviated new drug applications (ANDAs) since FY04.   

At 2.37 pm, the share price of Cadila Healthcare Ltd was trading at Rs 638.90, which was a decrease of 0.05 per cent over its previous day’s closing price of Rs 638.80 on BSE.